<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5741-22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ANAFRANIL TAB 10MG
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CLOMIPRAMINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        17.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            TEOFARMA S.R.L
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p> <em>Pharmacotherapeutic group: </em></p><p>Anafranil is available as tablets. The active substance in Anafranil is clomipramine hydrochloride, which belongs to group of medicines called tricyclic antidepressants.</p><p> <em>Therapeutic indications: </em></p><p>Anafranil is used to treat depression and mood disorders. Other psychological conditions that can be treated with Anafranil are obsessions, panic states and phobias (irrational fears), chronic painful conditions and muscular weakness (cataplexy) associated with repeat attacks of extreme sleepiness (narcolepsy) in adults. In children aged above 5 years, Anafranil is used to treat obsessions and bed-wetting.</p><p> <em>How Anafranil works </em></p><p>Anafranil is believed to work either by increasing the amount of naturally occurring chemical messengers (noradrenaline and serotonin) in the brain or by making their effects last longer.</p><p>If you have any questions about how Anafranil works or why this medicine has been prescribed for you, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>It is important to tell your doctor if you have other medical problems or if you are taking other medicines.</p><p>&nbsp;</p><p><strong>a. Do not take Anafranil</strong></p><p>Make sure your doctor knows:</p><p>&bull; If you are allergic (hypersensitive) to clomipramine, to any other tricyclic antidepressant, or to any of the other ingredients of Anafranil listed at the end of this leaflet.</p><p>&bull; If you are taking certain medicines used to treat depression such as monoamine oxidase inhibitors (MAO inhibitors), selective serotonin reuptake inhibitors (SSRI), or serotonin and noradrenergic reuptake inhibitors (SNaRI).</p><p>&bull; If you have recently had a heart attack or if you suffer from a serious heart disease.</p><p>If the answer to any of these is YES, Anafranil is probably not suitable for you.</p><p>If you think you may be allergic, ask your doctor for advice.</p><p>&nbsp;</p><p><strong>b. Take special care with Anafranil </strong></p><p>You should also inform your doctor if you suffer from any of the following:</p><p>&bull; If you are thinking about suicide,</p><p>&bull; If you have epileptic fits,</p><p>&bull; If you have irregular heart beat or other problems with your heart,</p><p>&bull; If you have schizophrenia or other mental disorder,</p><p>&bull; If you have glaucoma (increased pressure in the eye),</p><p>&bull; If you have liver or kidney disease,</p><p>&bull; If you have any blood disorder,</p><p>&bull; If you have difficulties in passing urine (e.g. due to diseases of the prostate),</p><p>&bull; If you have an overactive thyroid gland,</p><p>&bull; If you have persisting constipation,</p><p>&bull; If you easily faint.</p><p>Your doctor will take these conditions into account before and during your treatment with Anafranil.</p><p>If any of these apply to you, tell your doctor before you take Anafranil.</p><p>&nbsp;</p><p><strong>c. Information for families, and caregivers</strong></p><p>You should monitor whether your depressed child/patient shows signs of behavioural changes such as unusually anxiety, restlessness, sleeping problems, irritability, aggressiveness, over-excitedness or other unusual changes in behavior, worsening of depression or thinking about suicide. You should report any such symptoms to the patient&#39;s doctor, especially if they are severe, abrupt in onset, or were not part of the patient&#39;s presenting symptoms before. You should evaluate the emergence of such symptoms on a day-to-day basis, especially early during antidepressant treatment and when the dose is increased or decreased, since changes may be abrupt.</p><p>Symptoms such as these may be associated with an increased risk for suicidal thinking and behaviour and indicate a need for very close monitoring and possibly changes in the medication.</p><p>&nbsp;</p><p><strong>d. Older people</strong></p><p>Elderly patients generally need lower doses than young and middle-aged patients. Side effects are more likely to occur in older patients. Your doctor will provide any special information about careful dosage and close observation needed.</p><p>&nbsp;</p><p><strong>e. Children or adolescents &nbsp;</strong></p><p>Anafranil should not be given to children or adolescents unless specifically prescribed by a doctor. Your doctor will provide any special information about careful dosage and close observation needed.<em>&lt;Please tell your &lt;doctor, health care provider&gt; &lt;or&gt; &lt;pharmacist&gt; if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.&gt; </em></p><p>&nbsp;</p><p><strong>f. Pregnancy </strong></p><p>Tell your doctor if you are pregnant or breast-feeding. Anafranil should not be used during pregnancy unless specifically prescribed by your doctor.</p><p>Your doctor will discuss with you the potential risk of taking Anafranil during pregnancy.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>g. Breast-feeding <em>&nbsp;</em></strong></p><p>The active ingredient of Anafranil passes into the breast milk. Mothers are advised not to breast-feed their babies while taking Anafranil.</p><p>&nbsp;</p><p><strong>h. Driving and using machines </strong></p><p>Anafranil may make some people drowsy or less alert, or it may cause blurred vision. If this happens to you, do not drive, use machinery, or perform other tasks that need full attention. Drinking alcohol may increase drowsiness.</p><p>&nbsp;</p><p>i. Important information about some of the ingredients of Anafranil</p><p>Anafranil coated tablets contain lactose and sucrose. If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose, sucrose), contact your doctor before taking Anafranil coated tablets.</p><p>&nbsp;</p><p><strong>j. Taking other medicines</strong></p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. Remember also those not prescribed by a doctor.</p><p>Before starting treatment with Anafranil, tell your doctor or pharmacist about any other medicines that you may be using. Since many medicines interact with Anafranil, it may be necessary to adjust the dosage or stop one of the medicines. It is especially important for your doctor and pharmacist to know if you drink alcohol every day, if you change your smoking habits or if you are taking any of the following:</p><p>Medicines used to control blood pressure or heart function, other antidepressants, sedatives, tranquillizsers, anticonvulsants (e.g. barbiturates), antiepileptics, medicines used to prevent blood-clotting (anticoagulants), medicines used to treat asthma or allergies, medicines used to treat Parkinson&#39;s disease, thyroid preparations, medicines used to treat ulcer/heartburn such as cimetidine, a medicine called terbinafine used orally to treat skin, hair or nail infections due to fungus, medicines used to treat attention deficit/hyperactivity disorder such as methylphenidate, oral contraceptives, estrogens, medicines used to help the kidneys get rid of salt, and water by increasing the amount of urine produced (diuretics, also known as &ldquo;water pills&rdquo;), drugs used to reduce fat in blood, and grapefruit/grapefruit juice, cranberry juice.</p><p>&nbsp;</p><p><strong>k. Further safety measures</strong></p><p>It is important for your doctor to check your progress regularly to allow dosage adjustments and help reduce side effects. He or she may want to take some blood tests and measure your blood pressure and heart function before and during treatment.</p><p>Anafranil may cause dry mouth, which can increase the risk of tooth decay. This means that during long-term treatment you should have regular dental check-ups.</p><p>If you wear contact lenses and experience eye irritation, talk to your doctor.</p><p>Before you have any kind of surgery or dental treatment, tell the doctor in charge or dentist that you are taking Anafranil.</p><p>Anafranil may cause your skin to be more sensitive to sunlight. Stay out of direct sunlight, and wear protective clothing and sunglasses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Anafranil exactly as your doctor or health care provider has told you. You should check with your doctor, health care provider or pharmacist if you are not sure</p><p>Follow your doctor&rsquo;s instructions carefully. Do not exceed the recommended dosage.</p><p>Your doctor will decide on the most suitable dosage for your particular case. For depression, mood disorders, obsessive-compulsive disorders and phobias, the daily dosage is normally between 75 mg and 150 mg. For panic attacks and agoraphobia, treatment is usually started with 10 mg daily, and after a few days, the dosage is slowly increased to up to 100 mg. For chronic painful conditions, the daily dosage is usually between 10 mg and 150 mg. For bed-wetting in children (5 years or older), the daily dosage is usually between 20 mg and 75 mg, depending on the child&#39;s age.</p><p>Take Anafranil as directed by your doctor. Do not take more of it, and do not take it more often or for longer than your doctor ordered. In some cases the doctor may decide to treat you with injections of Anafranil.</p><p>You can take Anafranil with or without food.</p><p><strong>&nbsp;</strong></p><p><strong>Effects when treatment with Anafranil is stopped</strong></p><p>Depression, obsessive-compulsive disorders, and chronic anxiety states require long-term treatment with Anafranil. Do not change or stop the treatment without first asking your doctor. Your doctor may want you to reduce the dosage gradually before stopping completely. This is to prevent any worsening of your condition and reduce the risk of withdrawal symptoms such as headache, nausea, and general discomfort.</p><p><strong>&nbsp;</strong></p><p><strong>a. If you forget to take Anafranil</strong></p><p>If you forget to take a dose of Anafranil, take the missed dose as soon as possible and then go back to your normal dosage schedule. If it is almost time for your next dose, skip the missed dose and continue with your normal dosage schedule. If you have any questions about this, ask your doctor.</p><p>&nbsp;</p><p><strong>b. If you take more Anafranil than you should</strong></p><p>If you have accidentally taken too much Anafranil, talk to your doctor straight away. You may require medical attention.</p><p>The following symptoms of overdose usually appear within a few hours: severe drowsiness, poor concentration, fast, slow, or irregular heartbeat, restlessness and agitation, loss of muscle coordination and muscle stiffness, shortness of breath, fits, vomiting or fever.</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Anafranil can cause side effects, although not everybody gets them.</p><p>Anafranil can have some side effects in some people. These do not normally need medical attention, and may go away during treatment as your body adjusts to the medicine. Ask your doctor if any side effects continue or are bothersome.</p><p><strong>&nbsp;</strong></p><p><strong>Some side effects could be serious</strong></p><p>Seeing or hearing things that are not really there, a nervous system disorder characterized by muscle stiffness, high fever and impaired consciousness; jaundice, skin reactions (itching or reddening), frequent infection with fever and sore throat (due to decreased number of white blood cells), allergic reactions with/without coughing and difficulty in breathing, inability to coordinate movement, increase pressure in the eye, severe stomach pain, severe loss of appetite, sudden contraction of the muscles, muscle weakness or stiffness, muscle spasms, difficulty in passing urine, fast or irregular heartbeat (racing, pounding), difficulty in speaking, confusion, delirium, hallucinations, fits.</p><p><strong>If you experience any of these, tell your doctor straightaway.</strong></p><p><strong>Some side effects are very common (likely to affect more than 1 in 10 patients)</strong></p><p>Drowsiness, tiredness, dizziness, restlessness, increase in appetite, dry mouth, constipation, blurred vision, trembling, headache, nausea, sweating, weight gain, and sexual difficulties. At the start of treatment, Anafranil may increase your feelings of anxiety, but this effect generally disappears within two weeks.</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Some side effects are common (likely to affect between 1 and 10 patients in every 100 patients)</strong></p><p>Disorientation, agitation, palpitations, disturbance in attention, sleep disturbances, over-excitedness, aggressiveness, poor memory, yawning, nightmares, numbness or tingling of the extremities, hot flushes, dilated pupils, fall in blood pressure associated with dizziness after abrupt standing or sitting up, vomiting, abdominal disorders, diarrhoea, skin sensitivity to sunlight, worsening depression, swelling of the breasts and discharge of milk, unpleasant taste, ringing in the ears, irritability, feeling detached from a situation (like watching it from afar).</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Some side effects are uncommon (likely to affect between 1 and 10 patients in every 1000 patients)</strong></p><p>Fever, increase in blood pressure.</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Some side effects are very rare (likely to affect less than 1 in every 10,000 patients)</strong></p><p>Edema (swollen ankles and/or hands and/or swelling of any other part of the body), hair loss, Patients aged 50 years or older and taking a medicine of this group are more likely to experience bone fractures.</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Also reported (frequency not known)</strong></p><p>Feeling of inner restlessness and a compelling need to be in constant motion, repetitive, involuntary, purposeless movements, breakdown of muscle, increase in prolactin (a hormone) level in the blood, and serotonin syndrome (syndrome caused due to increase in naturally occurring messenger, serotonin, in brain; manifested by symptoms like agitation, confusion, diarrhoea, high temperature, increased blood pressure, excessive sweating and rapid heartbeat), delayed or no ejaculation of semen if you are a male.</p><p>If any of these affects you severely, <strong>tell your doctor.</strong></p><p>If you notice any other side effects not mentioned in this leaflet, please inform your doctor or pharmacist.</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><em>- Do not use after the expiry date shown on the box. The expiry date refers to the last day of that month. Remember to take back any unused medicine to your pharmacist.</em></p><p>- <em>store below 25&ordm; C, Store in the original package.</em></p><p>- <em>Keep out of the reach and sight of children. Overdose of this medicine is particularly dangerous in young children.</em></p><p><em>- The 25 mg coated tablets should be kept in a dry place.</em></p><p>- <em>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment. </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Anafranil is available in the following forms:</p><p>&bull; Coated tablets containing 10 mg or 25 mg clomipramine (Anafranil 10, Anafranil 25).</p><p>Anafranil tablets</p><p>&bull; The active substance of Anafranil is clomipramine.</p><p>&bull; The other ingredients are:</p><p>&bull; 10 mg and 25 mg Coated tablets: Lactose monohydrate, Maize starch, Hypromellose (hydroxypropyl methylcellulose), Magnesium stearate, Silica colloidal anhydrous, Talc, Copovidone (vinylpyrrolidone-vinylacetate copolymer), Titanium dioxide (E171), Sucrose, Povidone (polyvinylpyrrolidone), Iron oxide, yellow (E172), Macrogol 8000 (polyethylene glycol 8000), Cellulose microcrystalline.</p><p>&bull; The 25 mg Coated tablets also contain Stearic acid and Glycerol (85%).</p><p>This information might differ in some countries.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Anafranil 10 mg coated tablets:
Light yellow, triangular, biconvex tablets 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved by Novartis Pharmaceutical Company in 01/2015.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>ما هو أنافرانيل</strong></p><p>يتوافر أنافرانيل في شكل أقراص. المادة الفعالة في أنافرانيل هي كلوميبرامين هيدروكلوريد، وهي تنتمي إلى مجموعة من الأدوية تُسمَّى مضادات الاكتئاب ثلاثية الحلقات.</p><p>&nbsp;</p><p><strong>ما هي استعمالات أنافرانيل</strong></p><p>يُستعمَل أنافرانيل لعلاج الاكتئاب والاضطرابات المزاجية. الحالات النفسية الأخرى التي يمكن علاجها باستخدام أنافرانيل هي الوسواس القهري، حالات الهلع والرهاب (المخاوف غير المنطقية)، الحالات المؤلمة المزمنة والضعف العضلي (الجُمدة) المصحوبة بنوبات متكررة من النعاس المفرط (التغفيق) في البالغين. في الأطفال فوق 5 سنوات من العمر، يُستعمَل أنافرانيل لعلاج الوسواس القهري وسلس البول أثناء الليل.</p><p><strong>&nbsp;</strong></p><p><strong>كيف يعمل أنافرانيل</strong></p><p>من المعتقَد أن أنافرانيل يعمل إما من خلال زيادة كمية الموصلات الكيميائية الطبيعية (النورأدرينالين والسيروتونين) في الدماغ أو من خلال جعل مفعولها يستمر لمدة أطول.</p><p>إذا كانت لديك أي أسئلة عن الكيفية التي يعمل بها أنافرانيل أو عن سبب إعطائك هذا الدواء، اسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>التزم بتعليمات طبيبك بكل دقة. وهي قد تكون مختلفة عن التعليمات العامة المذكورة في هذه النشرة.</p><p>من المهم أن تخبر طبيبك إذا كانت لديك أي مشاكل صحية أخرى أو إذا كنت تتلقى أي أدوية أخرى.</p><p>&nbsp;</p><p><strong>لا تستعمل أنافرانيل:</strong></p><p>احرص على إبلاغ طبيبك:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت لديك أرجية</strong> (حساسية مفرطة) تجاه كلوميبرامين، أو تجاه أي دواء آخر مضاد للاكتئاب ثلاثي الحلقات، أو تجاه أي من المكونات الأخرى في أنافرانيل المذكورة في نهاية هذه النشرة.</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت</strong> تستعمل أدوية معيَّنة لعلاج الاكتئاب مثل مثبطات أحادي أمين أوكسيديز (مثبطات MAO)، أو المثبطات الانتقائية لإعادة التقاط السيروتونين (SSRI)، أو مثبطات إعادة التقاط السيروتونين والنورأدرينالين (SNaRI).</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت</strong> قد أُصبت منذ فترة قصيرة بنوبة قلبية، أو إذا كنت تعاني من مرض قلبي خطير.</p><p>إذا كانت إجابتك &quot;نعم&quot; على أي من هذه الأسئلة، فمن المرجَّح أن يكون أنافرانيل غير مناسب لك.</p><p>إذا ظننت أن لديك أرجية (حساسية مفرطة) استشر طبيبك.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>يجب توخي الحذر الخاص مع </strong><strong>أنافرانيل:</strong></p><p>يجب أيضاً أن تخبر طبيبك إذا كنت تعاني من أي من الحالات التالية:</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تفكر في الانتحار،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك نوبات صرع،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك عدم انتظام في ضربات القلب أو مشاكل أخرى في القلب،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك فصام أو أي مرض عقلي آخر،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك جلوكوما (ارتفاع الضغط في العين)،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض كبدي أو كلوي،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أي مرض في الدم،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك صعوبة في إفراز البول (مثلاً بسبب أمراض في البروستاتا)،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك نشاط زائد في الغدة الدرقية،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك إمساك مستمر،</p><p>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك قابلية للإغماء.</p><p>سوف يضع طبيبك هذه الأحوال في اعتباره قبل وأثناء علاجك بأنافرانيل.</p><p>إذا انطبق عليك أي من هذه الأمور، <strong>أخبر طبيبك قبل أن تستعمل</strong> أنافرانيل.</p><p>&nbsp;</p><p><strong>معلومات للأسرة ولمقدمي الرعاية الصحية</strong></p><p>يجب أن تراقب مريض الاكتئاب الذي تحت رعايتك سواء كان طفلاً أو بالغاً من جهة حدوث تغيرات سلوكية مثلاً في شكل قلق غير معتاد، تململ، مشاكل في النوم، تهيج، عدوانية، إثارة مفرطة، أو تغيرات أخرى غير معتادة في السلوك، أو اشتداد الاكتئاب أو التفكير في الانتحار. يجب إبلاغ الطبيب عند حدوث أي من هذه الأعراض، لا سيما إذا كانت شديدة، أو مفاجئة، أو لم تكن من بين الأعراض التي كانت تحدث لدى المريض من قبل. يجب عليك تقييم حدوث هذه الأعراض على أساس يومي، لا سيما في بداية العلاج بمضاد الاكتئاب وعند زيادة الجرعة أو خفضها، وذلك لأن التغيرات قد تكون مفاجئة.</p><p>هذه الأعراض قد تكون مصحوبة بزيادة في مخاطرة التفكير الانتحاري والسلوك الانتحاري وهي تُشير إلى الحاجة للمراقبة الدقيقة جداً وربما الحاجة لتغيير الدواء.</p><p>&nbsp;</p><p><strong>الأشخاص المسنون</strong></p><p>يحتاج المرضى المسنون بصفة عامة إلى جرعات أقل من المرضى في السن الصغير والمتوسط. الآثار الجانبية أكثر قابلية للحدوث في المرضى الأكبر سناً. سيعطيك طبيبك معلومات محددة عن الجرعة المطلوبة بالضبط وعن المراقبة الدقيقة.</p><p>&nbsp;</p><p><strong>الأطفال أو المراهقون</strong></p><p>لا ينبغي إعطاء أنافرانيل للأطفال أو المراهقين ما لم يصفه الطبيب بشكل محدد. سيعطيك طبيبك أي معلومات محددة عن الجرعة المطلوبة بالضبط وعن المراقبة الدقيقة.</p><p>&nbsp;</p><p><strong>الحمل</strong></p><p>أخبري طبيبك إذا كنت حاملاً أو مرضعة. لا ينبغي استعمال أنافرانيل أثناء الحمل ما لم يصفه طبيبك بشكل محدد.</p><p>سيناقش معك طبيبك المخاطر الممكنة التي قد تترتب على إعطائك أنافرانيل أثناء الحمل.</p><p>&nbsp;</p><p><strong>الإرضاع</strong></p><p>المادة الفعالة في أنافرانيل تنفذ إلى لبن الثدي. يوصَى بأن تمتنع الأمهات عن إرضاع أطفالهن من الثدي أثناء استعمال أنافرانيل.</p><p>&nbsp;</p><p><strong>قيادة السيارة وتشغيل الآلات</strong></p><p>قد يؤدي أنافرانيل في بعض الأشخاص إلى حدوث دوخة، أو نقص اليقظة، أو غشاوة في الإبصار. إذا حدث هذا لديك، امتنع عن قيادة السيارة، أو تشغيل الآلات، أو أداء المهام الأخرى التي تتطلب يقظة تامة. قد يؤدي شُرب الكحول إلى زيادة الدوخة.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>معلومات هامة عن بعض المكونات في أنافرانيل</strong></p><p>تحتوي أقراص أنافرانيل المغلَّفة على لاكتوز وسيكروز. إذا كان طبيبك قد أخبرك بأن لديك عدم تحمُّل لبعض أنواع السكر (مثل اللاكتوز، السيكروز)، اتصل بطبيبك قبل أن تأخذ أقراص أنافرانيل المغلَّفة.</p><p>&nbsp;</p><p><strong>استعمال أدوية أخرى</strong></p><p><strong>أخبر طبيبك أو الصيدلي</strong> إذا كنت تستعمل حالياً أو إذا كنت قد استعملت منذ فترة قصيرة أي أدوية أخرى. تذكر أيضاً الأدوية التي لم يصفها لك الطبيب، ويشمل ذلك الأدوية التي يتم الحصول عليها بدون تذكرة طبية.</p><p>قبل البدء في استعمال أنافرانيل، أخبر طبيبك أو الصيدلي عن أي أدوية أخرى تستعملها. حيث أن العديد من الأدوية يتداخل في مفعوله مع أنافرانيل، قد يلزم تعديل جرعة أحد الأدوية أو وقف استعماله. من المهم على نحو خاص أن تخبر طبيبك والصيدلي إذا كنت تشرب الكحول يومياً، أو إذا غيرت عاداتك في التدخين، أو إذا كنت تستعمل أي مما يلي:</p><p>الأدوية التي تُستعمَل للسيطرة على ضغط الدم أو وظيفة القلب، الأدوية الأخرى المضادة للاكتئاب، المنومات، المهدئات، مضادات التشنجات (مثلاً الباربيتيورات)، مضادات الصرع، الأدوية التي تُستعمَل لمنع تجلط الدم (مضادات التجلط)، الأدوية التي تُستعمَل لعلاج الربو أو الحساسية، الأدوية التي تُستعمَل لعلاج مرض باركنسون، المستحضرات الدرقية، الأدوية التي تُستعمَل لعلاج قرحة المعدة/ الحُرقة في فم المعدة مثل سيميتيدين، دواء يُسمى تربينافين يؤخذ بالفم لعلاج العدوى الفطرية في الجلد، أو الشعر، أو الأظافر، الأدوية التي تُستعمَل لعلاج اضطراب نقص الانتباه/ النشاط المفرط مثل ميثيل فينيدات، أقراص منع الحمل التي تؤخذ بالفم، الإستروجين، الأدوية التي تُستعمَل لمساعدة الكلى على التخلص من الملح والماء من خلال زيادة إفراز البول (مدرات البول)، الأدوية التي تُستعمَل لخفض الدهون في الدم، الجريب فروت/ عصير الجريب فروت، عصير التوت البري.</p><p>&nbsp;</p><p><strong>إجراءات أمان إضافية</strong></p><p>من المهم أن يقوم طبيبك بفحص تقدمك بصفة دورية مما يتيح إمكانية تعديل الجرعة ويساعد على تقليل الآثار الجانبية. وهو قد يرغب في إجراء بعض اختبارات الدم وقياس ضغط الدم ووظيفة القلب لديك قبل وأثناء تلقي العلاج.</p><p>قد يؤدي أنافرانيل إلى جفاف الفم، مما يُزيد من مخاطرة تسوس الأسنان. هذا يعني أنك أثناء العلاج المطوَّل يجب أن تخضع لفحص الأسنان بصفة منتظمة.</p><p>إذا كنت ترتدي عدسات لاصقة وحدث لك تهيج في العين، تحدث مع طبيبك.</p><p>قبل أن تُجرَى لك أي عملية جراحية أو علاج للأسنان، أخبر الطبيب المسئول أو طبيب الأسنان بأنك تستعمل أنافرانيل.</p><p>قد يجعل أنافرانيل جلدك أكثر حساسية لضوء الشمس. يوصَى بالابتعاد عن ضوء الشمس المباشر، وبارتداء ملابس واقية ونظارة شمسية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>التزم بتعليمات طبيبك بكل دقة. لا تتجاوز الجرعة الموصَى بها.</p><p>سوف يحدد طبيبك الجرعة المناسبة لحالتك بالتحديد. في حالات الاكتئاب، والاضطرابات المزاجية، والوسواس القهري، وحالات الرهاب، تتراوح الجرعة اليومية عادةً بين 75 مجم و 150 مجم. في نوبات الهلع ورهاب الأماكن الواسعة، يتم بدء العلاج عادةً بالجرعة 10 مجم يومياً، وبعد بضعة أيام تُزاد الجرعة ببطء حتى 100 مجم. في الحالات المؤلمة المزمنة، تتراوح الجرعة اليومية عادةً بين 10 مجم و 150 مجم. في حالات سلس البول الليلي في الأطفال (5 سنوات من العمر أو أكثر)، تتراوح الجرعة اليومية عادةً بين 20 مجم و 75 مجم، وفقاً لسن الطفل.</p><p>خذ أنافرانيل بحسب توجيهات طبيبك. لا تأخذ أكثر مما أوصى به طبيبك، ولا تأخذه بشكل أكثر تكراراً أو لمدة أطول مما أوصى به طبيبك. في بعض الحالات قد يقرر طبيبك أن يعطيك أنافرانيل عن طريق الحقن.</p><p>يمكنك أن تأخذ أنافرانيل مع الطعام أو بدونه.</p><p>&nbsp;</p><p><strong>الآثار التي تحدث عند وقف استعمال </strong><strong>أنافرانيل</strong></p><p>تحتاج حالات الاكتئاب، والوسواس القهري، والقلق المزمن، إلى استعمال أنافرانيل لمدة طويلة. لا تغير العلاج ولا توقفه بدون أن تسأل طبيبك أولاً. قد يرغب طبيبك في خفض الجرعة بالتدريج قبل أن يوقف العلاج تماماً، وذلك لتجنب أي تفاقم لحالتك ولتقليل مخاطرة حدوث أعراض انسحابية مثل الصداع، والغثيان، والعناء العام.</p><p><strong>إذا نسيت أن تأخذ أنافرانيل</strong></p><p>إذا نسيت أن تأخذ إحدى جرعات أنافرانيل، خذ الجرعة المنسية في أقرب وقت ممكن ثم استأنف نظامك المعتاد في أخذ الدواء. إذا كان موعد جرعتك اللاحقة قد اقترب، تغاضى عن الجرعة المنسية واستمر في نظامك المعتاد في أخذ الدواء. إذا كانت لديك أي أسئلة بهذا الشأن، اسأل طبيبك.</p><p>&nbsp;</p><p><strong>إذا أخذت أنافرانيل بأكثر مما ينبغي</strong></p><p>إذا أخذت أنافرانيل بأكثر مما ينبغي على سبيل الخطأ، اتصل بطبيبك <strong>فوراً</strong>، فإنك قد تحتاج إلى رعاية طبية.</p><p>الأعراض التالية المتعلقة بتجاوز الجرعة تظهر عادةً خلال ساعات قليلة: نعاس شديد، ضعف التركيز، تسرع أو بطء أو عدم انتظام ضربات القلب، تململ وهياج، فقدان التناسق العضلي، تيبس عضلي، ضيق في التنفس، تشنجات، قيء، أو حمى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يؤدي أنافرانيل إلى حدوث بعض الآثار الجانبية في بعض الأشخاص. هذه الآثار الجانبية لا تحتاج عادةً إلى رعاية طبية، وقد تزول مع استمرار العلاج بأن يتكيف جسمك مع الدواء. اسأل طبيبك إذا استمرت الآثار الجانبية أو إذا كانت مزعجة.</p><p>&nbsp;</p><p><strong>بعض الآثار الجانبية قد تكون خطيرة</strong></p><p>مشاهدة أو سماع أشياء غير موجودة في الحقيقة، اضطراب في الجهاز العصبي يتصف بالتيبس العضلي، والحمى المرتفعة، وضعف الوعي؛ يرقان، تفاعلات جلدية (حكة أو احمرار)، عدوى متكررة مصحوبة بحمى والتهاب الحلق (بسبب نقص عدد خلايا الدم البيضاء)، تفاعلات أرجية (حساسية مفرطة) مع/ بدون سعال وصعوبة في التنفس، عدم القدرة على تناسق الحركة، ارتفاع الضغط في العين، ألم شديد في المعدة، فقدان شديد للشهية، انقباض مفاجئ للعضلات، ضعف عضلي أو تيبس عضلي، تشنجات عضلية، صعوبة في التبول، تسرع أو عدم انتظام ضربات القلب (تسرع، خفقان)، صعوبة في الكلام، تشويش، هذيان، هلاوس، نوبات.</p><p><strong>إذا حدث لديك أي من هذه الأمور، أخبر طبيبك فوراً.</strong></p><p>&nbsp;</p><p><strong>بعض الآثار الجانبية تكون شائعة جداً (يُرجَّح أن تُصيب أكثر من 1 من بين 10 مرضى)</strong></p><p>نعاس، تعب، دوخة، تململ، زيادة الشهية، جفاف الفم، إمساك، غشاوة في الإبصار، رعشة، صداع، غثيان، تعرق، زيادة الوزن، صعوبات جنسية. عند بدء العلاج، قد يؤدي أنافرانيل إلى زيادة مشاعر القلق لديك، ولكن هذا التأثير يزول عادةً خلال أسبوعين.</p><p>إذا حدثت لديك إصابة شديدة بأي من هذه الأمور، <strong>أخبر طبيبك</strong>.</p><p>&nbsp;</p><p><strong>بعض الآثار الجانبية تكون شائعة (يُرجَّح أن تُصيب بين 1 و 10 مرضى من كل 100 مريض)</strong></p><p>توهان، هياج، خفقان، خلل في الانتباه، اضطرابات في النوم، إثارة مفرطة، عدوانية، ضعف الذاكرة، تثاؤب، كوابيس، خدر أو تنميل في الأطراف، توهجات ساخنة، اتساع حدقة العين، انخفاض ضغط الدم مصحوب بدوخة عقب الوقوف المفاجئ أو الجلوس من وضع الاستلقاء، قيء، اضطرابات في البطن، إسهال، حساسية جلدية لضوء الشمس، اشتداد الاكتئاب، انتفاخ الثديين وإفراز اللبن، مذاق بغيض، طنين في الأذنين، تهيج، الشعور بالانفصال عن الموقف (وكأن الشخص يشاهد الموقف من بعيد).</p><p>إذا حدثت لديك إصابة شديدة بأي من هذه الأمور، <strong>أخبر طبيبك</strong>.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>بعض الآثار الجانبية تكون غير شائعة (يُرجَّح أن تُصيب بين 1 و 10 مرضى من كل 1000 مريض)</strong></p><p>حمى، ارتفاع ضغط الدم.</p><p>إذا حدثت لديك إصابة شديدة بأي من هذه الأمور، <strong>أخبر طبيبك</strong>.</p><p>&nbsp;</p><p><strong>بعض الآثار الجانبية تكون نادرة جداً (يُرجَّح أن تُصيب أقل من 1 من كل 10000 مريض)</strong></p><p>وذمة (تورم الكاحلين و/أو اليدين و/أو تورم أي جزء آخر في الجسم)، سقوط الشعر، المرضى الذين يبلغون من العمر 50 سنة أو أكثر ويستعملون دواءً من هذه المجموعة يكونون أكثر قابلية للإصابة بكسور في العظم.</p><p>إذا حدثت لديك إصابة شديدة بأي من هذه الأمور، <strong>أخبر طبيبك</strong>.</p><p>&nbsp;</p><p><strong>آثار جانبية أخرى تم الإبلاغ عنها (معدل الحدوث غير معروف)</strong></p><p>الإحساس بالتململ الداخلي والرغبة الملحة في الحركة المستمرة، حركات متكررة لاإرادية وغير هادفة، انحلال العضلات، زيادة مستوى البرولاكتين (هرمون) في الدم، متلازمة السيروتونين (متلازمة ناتجة عن زيادة في الناقل الطبيعي، السيروتونين، في الدماغ؛ تظهر أعراضها في شكل هياج، تشويش، إسهال، ارتفاع حرارة الجسم، ارتفاع ضغط الدم، تعرق مفرط، زيادة سرعة ضربات القلب)، تأخر أو انعدام قذف السائل المنوي في الذكور.</p><p>إذا حدثت لديك إصابة شديدة بأي من هذه الأمور، <strong>أخبر طبيبك</strong>.</p><p>إذا لاحظت أي آثار جانبية أخرى غير مذكورة في هذه النشرة، برجاء أن تخبر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا ينبغي استعماله بعد تاريخ انتهاء الصلاحية المذكور على العلبة الخارجية. تذكر أن تُعيد إلى الصيدلي أي جزء غير مستخدَم من الدواء.</p><p>يخزن في درجة حرارة أقل من 25 &ordm; مئوية</p><p>يُحفَظ في عبوته الأصلية.</p><p>يُحفظ بعيداً عن متناول ومرأى الأطفال. الجرعة المفرطة من هذا الدواء تمثل خطورة خاصة على الأطفال الصغار.</p><p>الأقراص المغلَّفة 25 مجم يجب أن تُحفَظ في مكان جاف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يتوافر أنافرانيل في الأشكال التالية:</p><p>أقراص مغلَّفة تحتوي على 10 مجم أو 25 مجم كلوميبرامين (أنافرانيل 10، أنافرانيل 25).</p><p>&nbsp;</p><p><strong>أنافرانيل أقراص</strong></p><p><strong>المادة الفعالة</strong> في أنافرانيل هي كلوميبرامين.</p><p>المكونات الأخرى هي:</p><p>الأقراص المغلَّفة 10 مجم و 25 مجم: لاكتوز مونوهيدرات، نشا الذرة، هيبروميلوز (هيدروكسي بروبيل ميثيل سيليلوز)، ستيارات ماغنسيوم، سيليكا غروانية لامائية، تلك، كوبوفيدون (كوبوليمر فينيل بايروليدين- فينيل أسيتات)، ثاني أكسيد التيتانيوم (E 171)، سيكروز، بوفيدون (بولي فينيل بايروليدين)، أكسيد الحديد الأصفر (E 172)، ماكروجول 8000 (بولي إيثيلين جلايكول 8000)، سيليلوز دقيق التبلور.</p><p>الأقراص المغلَّفة 25 مجم تحتوي أيضاً على حمض ستياريك وجليسرول (85%).</p><p>&nbsp;</p><p>هذه المعلومات قد تختلف في بعض البلاد.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            أقراص صفراء، دائرية، ثنائية التحدب، مرمزة بطابع بني "CG" في جهة واحدة و"FH" في الجهة الأخرى.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التَّسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p>www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            د‌.	تم آخر اعتماد لهذه النَّشرة من قبل شركة نوفارتس للأدوية في تاريخ 01/2015.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ANAFRANIL® 10 mg coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each coated tablet contains 10 mg or 25 mg clomipramine hydrochloride.
For a full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Coated tablets 
Anafranil 10 mg coated tablets:
Light yellow, triangular, biconvex tablets 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults</strong></p><p>Treatment of depressive states of varying aetiology and symptomatology, e.g.:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depressive syndromes - mild, moderate and severe, with and without psychotic symptoms, with recurrent depression or bipolar affective disorder;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression associated with schizophrenia and personality disorders.</p><p>Obsessive-compulsive syndromes, phobias and panic attacks. Cataplexy accompanying narcolepsy.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>In children and adolescents, there is not sufficient evidence of safety and efficacy of Anafranil in the treatment of depressive states of varying aetiology and symptomatology, phobias and panic attacks, cataplexy accompanying narcolepsy and chronic painful conditions. The use of Anafranil in children and adolescents (0-17 years of age) in these indications is therefore not recommended (see section 4.4.).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before initiating treatment with Anafranil, hypokalaemia should be treated (see section 4.4).The dosage should be adapted to the individual patient&#39;s condition. The aim is to achieve an optimum effect while keeping the doses as low as possible.</p><p>&nbsp;</p><p>After a response has been obtained, maintenance therapy should be continued at the optimum dose to avoid relapse. Patients with a history of recurrent depression require maintenance treatment for a longer duration. Duration of maintenance treatment and need for further treatment should be reviewed periodically. As a precaution against possible QTc prolongation and serotonergic toxicity, adherence to the recommended doses of Anafranil is advised and any increase in dose should be made with caution if drugs that prolong QT interval or other serotonergic agents are co-administered (see sections 4.4 and 4.5).</p><p>Abrupt discontinuation of Anafranil therapy should be avoided because of possible withdrawal symptoms. Therefore, dosage should be stopped gradually after regular use for long duration and the patient should be monitored carefully when Anafranil therapy is discontinued.</p><p>&nbsp;</p><p><strong>Depression, obsessive-compulsive syndromes, and phobias</strong></p><p>Start treatment with 1 coated tablet of 25&nbsp;mg 2-3&nbsp;times daily. Raise the daily dosage stepwise, e.g. 25&nbsp;mg every few days, (depending on how the medication is tolerated) to 100-150&nbsp;mg in the end of the first week of treatment. In severe cases this dosage can be increased up to a maximum of 250&nbsp;mg daily. Once there is a distinct improvement, adjust the daily dosage to a maintenance level of about 50-100 mg..</p><p>&nbsp;</p><p><strong>Panic attacks and agoraphobia</strong></p><p>Start with 10&nbsp;mg daily. Depending on how the medication is tolerated, raise the dosage until the desired response is obtained. The daily dosage required varies greatly from patient to patient and lies between 25 and 100&nbsp;mg. If necessary it can be increased up to 150&nbsp;mg. It is advisable for treatment not to be discontinued for at least 6&nbsp;months and for the maintenance dose to be reduced slowly during this time.</p><p>&nbsp;</p><p><strong>Cataplexy accompanying narcolepsy</strong></p><p>Daily dose of 25-75&nbsp;mg.</p><p>&nbsp;</p><p><strong>Dosage and administration in special populations</strong></p><p><strong>&nbsp;</strong></p><p><strong>Elderly patients (65 years or older)</strong></p><p>Elderly patients generally show a stronger response to Anafranil than patients of intermediate age groups, Anafranil should be used with caution in elderly patients and doses should be increased cautiously. Start treatment with 10&nbsp;mg daily. Gradually raise the dosage to an optimum level of 30-50&nbsp;mg daily, which should be reached after about 10 days and then maintained until the end of treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p>Adolescents generally show a stronger response to Anafranil than patients of intermediate age groups, Anafranil should be used with caution in adolescents and doses should be increased cautiously.</p><p>&nbsp;</p><p><strong>Obsessive-compulsive syndromes</strong></p><p>The starting dose is 25 mg daily and should be gradually increased (given in divided doses) during the first 2 weeks, as tolerated, up to a daily maximum of 3 mg/kg or 100 mg, whichever is smaller. Thereafter, the dosage may be increased gradually over the next several weeks up to a daily maximum of 3 mg/kg or 200 mg, whichever is smaller</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Renal impairment</strong></p><p>Anafranil should be given with caution in patients with renal impairment (see section 4.4 Special warnings and precautions for use.)</p><p>&nbsp;</p><p><strong>Hepatic impairment</strong></p><p>Anafranil should be given with caution in patients with hepatic impairment (see section 4.4 Special warnings and precautions for use.)</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>The dose should be adapted to the individual patient&#39;s condition.</p><p>Anafranil can be administered with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to clomipramine or any of the excipients, or cross-sensitivity to tricyclic antidepressants of the dibenzazepine group.
Anafranil should not be given in combination, or within 14 days before or after treatment, with a MAO inhibitor (see section 4.5). The concomitant treatment with selective, reversible MAO-A inhibitors, such as moclobemide, is also contraindicated.
Recent myocardial infarction.
Congenital long QT syndrome

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Suicide/suicidal thoughts or clinical worsening</strong></p><p>Depression is associated with increased risk of suicidal thoughts, self-harm and suicide (events relating to suicide). This risk persists until significant remission occurs. Patients with depressive disorders, both adult and paediatric, may experience worsening of depression and/or suicidality or other psychiatric symptoms, whether or not they are taking antidepressant medication. Antidepressants increased the risk of suicidal thinking and behaviour (suicidality) in short-term studies in children, adolescents and young adults less than 25 years old with depressive disorders and other psychiatric disorders.</p><p>All patients being treated with Anafranil for any indication should be observed closely for clinical worsening, suicidality and other psychiatric symptoms (see section 4.8 Adverse drug reactions), especially during the initial phase of therapy or at times of dose changes.</p><p>&nbsp;</p><p>&nbsp;</p><p>It must be taken into account the possibility of changing the dosage including the possibility of discontinuing therapy in patients with severe, abrupt changes at treatment beginning or changes which are not part of current symptoms (see also Treatment discontinuing in section 4.4. Special warnings and precautions for use).</p><p>&nbsp;</p><p>The patients being treated with antidepressants for both psychiatric and non-psychiatric indications as well as the families and caregivers of those patients, should be alerted about the need to monitor patients for the emergence of other psychiatric symptoms (see section 4.8 Adverse drug reactions), as well as the emergence of suicidality, and to report such symptoms immediately to health care providers.</p><p>&nbsp;</p><p>Anafranil should be prescribed in the lowest available dose of tablets in order to avoid overdose and abuse. There is evidence that the application of Anafranil is associated with fewer deaths due to overdose, compared with other tricyclic antidepressants</p><p>&nbsp;</p><p><strong>Children and adolescents </strong><strong>(</strong><strong>0-17&nbsp;years of age</strong><strong>)</strong></p><p>Anafranil should not be used to treat depression, phobias and cataplexy associated with narcolepsy in children under 18 years of age (see section 4.1).</p><p>Antidepressants increase the risk of suicidal behavior (attempts and suicidal thoughts) and hostility (predominantly aggression, oppositional behavior and anger) are more frequently observed in clinical trials in children, adolescents and young people under 25 years treated with antidepressants compared to those treated with placebo. However if based on clinical need, a decision to carry out treatment, the patient should be carefully monitored for the appearance of suicidal symptoms. Moreover, long-term safety data in children and adolescents concerning growth, maturation and cognitive-behavioral development are insufficient.</p><p>Families and caregivers of paediatric and adult patients treated with antidepressants because of both psychiatric and due to non-psychiatric testimony, should be alert about the need to monitor patients for the emergence of psychiatric symptoms (see section 4.8) and suicidality and to report immediately the occurrence of such symptoms to health professionals</p><p>&nbsp;</p><p><strong>Other psychiatric effects</strong></p><p>Many patients with panic disorder experience more marked anxiety at the start of the treatment with Anafranil (section 4.2).</p><p>This paradoxical initial increase in anxiety is most pronounced during the first few days of treatment and generally subsides within two weeks.</p><p>Activation of psychosis has occasionally been observed in patients with schizophrenia receiving tricyclic antidepressants.</p><p>Hypomanic or manic episodes have also been reported during a depressive phase in patients with cyclic affective disorders receiving treatment with a tricyclic antidepressant.</p><p>In such cases it may be necessary to reduce the dosage of Anafranil or to withdraw it and administer an antipsychotic agent. After such episodes have subsided, low dose therapy with Anafranil may be resumed if required.</p><p>In predisposed and elderly patients, tricyclic antidepressants may provoke pharmacogenic (delirious) psychoses, particularly at night. These disappear within a few days of withdrawing the drug.</p><p>&nbsp;</p><p><strong>Cardiac and vascular disorders</strong></p><p>Anafranil should be administered with particular caution in patients with cardiovascular disorders, especially those with cardiovascular insufficiency, conduction disorders, (e.g. atrioventricular block grades I to III), or arrhythmias. Monitoring of cardiac function and the ECG is indicated in such patients, as well as in elderly patients.</p><p>There may be a risk of QTc prolongation and torsades de pointes, particularly at supra-therapeutic doses or supra-therapeutic plasma concentrations of clomipramine, as occur in the case of co-medication with selective serotonin reuptake inhibitors (SSRIs) or serotonin and noradrenergic reuptake inhibitors (SNaRIs). Therefore, concomitant administration of drugs that can cause accumulation of clomipramine should be avoided. Equally, concomitant administration of drugs that can prolong the QTc interval should be avoided (see sections 4.2 and 4.5.). It is established that hypokalaemia is a risk-factor of QTc prolongation and torsades de pointes. Therefore, hypokalaemia should be treated before initiating treatment with Anafranil (see sections 4.2 and 4.5).</p><p>&nbsp;</p><p>Before starting treatment with Anafranil, it is advisable to check blood pressure because patients with postural hypotension or a labile circulation may experience a fall in blood pressure.</p><p>&nbsp;</p><p><strong>Serotonin syndrome</strong></p><p>Due to the risk of serotonergic toxicity, it is advisable to adhere to recommended doses. Serotonin Syndrome, with symptoms such as hyperpyrexia, myoclonus, agitation, seizures, delirium and coma, can possibly occur when clomipramine is administered with serotonergic co-medications such as SSRIs, SNaRIs, tricyclic antidepressants or lithium (see sections 4.2 and 4.5). For fluoxetine a washout period of two to three weeks is advised before and after treatment with fluoxetine.</p><p>&nbsp;</p><p><strong>Convulsions</strong></p><p>Tricyclic antidepressants are known to lower the convulsion threshold and Anafranil should, therefore, be used with extreme caution in patients with epilepsy and other predisposing factors, e.g. brain damage of varying aetiology, concomitant use of neuroleptics, withdrawal from alcohol or drugs with anticonvulsive properties (e.g. benzodiazepines). It appears that the occurrence of seizures is dose dependent. Therefore, the recommended total daily dose of Anafranil should not be exceeded.</p><p>Like related tricyclic antidepressants, Anafranil should be given with electroconvulsive therapy only under careful supervision.</p><p>&nbsp;</p><p><strong>Anticholinergic effects</strong></p><p>Because of its anticholinergic properties, Anafranil should be used with caution in patients with a history of increased intraocular pressure, narrow-angle glaucoma, or urinary retention (e.g. diseases of the prostate).</p><p>Decreased lacrimation and accumulation of mucoid secretions due to the anticholinergic properties of tricyclic antidepressants may cause damage to the corneal epithelium in patients with contact lenses.</p><p>&nbsp;</p><p><strong>Specific treatment populations</strong></p><p>Caution is called for when giving tricyclic antidepressants to patients with severe hepatic disease and tumours of the adrenal medulla (e.g. phaeochromocytoma, neuroblastoma), in whom they may provoke hypertensive crises.</p><p>Caution is indicated in patients with hyperthyroidism or patients receiving thyroid preparations, owing to the possibility of cardiac toxicity.</p><p>In patients with hepatic and renal disease, periodic monitoring of the hepatic enzyme levels and renal function is recommended.</p><p>Caution is called for in patients with chronic constipation. Tricyclic antidepressants may cause paralytic ileus, particularly in elderly and in bedridden patients.</p><p>An increase in dental caries has been reported during long-term treatment with tricyclic antidepressants. Regular dental check-ups are therefore advisable during long-term treatment.</p><p>Long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are not available.</p><p>&nbsp;</p><p><strong>White</strong><strong> </strong><strong>blood</strong><strong> </strong><strong>cell</strong><strong> </strong><strong>count</strong></p><p>Although changes in the white blood cell count have been reported with Anafranil only in isolated cases, periodic blood cell counts and monitoring for symptoms such as fever and sore throat are called for, particularly during the first few months of therapy and during prolonged treatment &nbsp;</p><p>&nbsp;</p><p><strong>Anesthesia</strong></p><p>Before general or local anesthesia, the anesthesist should be told that the patient has been receiving ANAFRANIL (see section 4.5).</p><p><strong>&nbsp;</strong></p><p><strong>Treatment discontinuation</strong></p><p>Abrupt withdrawal should be avoided because of possible adverse reactions. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see section 4.8 &nbsp;.</p><p>&nbsp;</p><p><strong>Lactose and sucrose</strong></p><p>Anafranil coated tablets contain lactose and sucrose. Patients with rare hereditary problems of galactose intolerance, fructose intolerance, severe lactase deficiency, sucrase-isomaltase insufficiency or glucose-galactose malabsorption should not take Anafranil coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Interactions resulting in a contraindication</u></p><p><strong><em>MAO inhibitors</em></strong></p><p>Do not give Anafranil for at least 2 weeks after discontinuation of treatment with MAO inhibitors (there is a risk of severe symptoms such as hypertensive crisis, hyperpyrexia and those consistent with serotonin syndrome, e.g. myoclonus, agitation seizures, delirium and coma). MAO inhibitors, which are also potent CYP2D6 inhibitors <em>in vivo</em>, such as moclobemide, are contraindicated for coadministration with clomipramine (see section 4.3). The same applies when giving a MAO inhibitor after previous treatment with Anafranil. In both instances Anafranil or the MAO inhibitor should initially be given in small, gradually increasing doses and its effects monitored (see section &nbsp;4.3).</p><p>There is evidence to suggest that Anafranil may be given as little as 24 hours after a reversible MAO-A inhibitor such as moclobemide, but the two-week washout period must be observed if the MAO-A inhibitor is given after Anafranil has been used.</p><p>&nbsp;</p><p><u>Interactions resulting in a concomitant use not recommended</u><u> </u></p><p><strong>&nbsp;</strong></p><p><strong><em>Antiarrhythmics</em></strong></p><p>Antiarrhythmics (such as quinidine and propafenone) which are potent inhibitors of CYP2D6, should not be used in combination with tricyclic antidepressants.</p><p><strong>&nbsp;</strong></p><p><strong><em>Diuretics</em></strong></p><p>Diuretics may lead to hypokalaemia, which in turn increases the risk of QTc prolongation and torsades de pointes. Hypokalaemia should therefore be treated prior to administration of Anafranil (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><strong><em>Selective serotonin reuptake inhibitors (SSRIs)</em></strong></p><p>SSRIs which are inhibitors of CYP2D6, such as fluoxetine, paroxetine, or sertraline, and of others including CYP1A2 and CYP2C19 (e.g. fluvoxamine), may also increase plasma concentrations of clomipramine, with corresponding adverse effects. Steady-state serum levels of clomipramine increased ~4-fold by co-administration of fluvoxamine (<em>N</em>-desmethylclomipramine decreased ~2-fold). In addition, comedication with SSRIs may lead to additive effects on the serotonergic system (see serotonergic agents). (See sections 4.2 Posology and method of administration and 4.4 Special warnings and precautions for use).</p><p><strong>&nbsp;</strong></p><p><strong><em>Serotonergic agents</em></strong></p><p>Serotonin syndrome can possibly occur when clomipramine is administered with serotonergic co-medications such as selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenergic reuptake inhibitors (SNaRIs), tricyclic antidepressants or lithium (see sections 4.2 and 4.4). For fluoxetine, a washout period of two to three weeks is advised before and after treatment with fluoxetine.</p><p>&nbsp;</p><p><u>Interactions to be considered</u></p><p>&nbsp;</p><p><em>Interactions resulting in increased effect of Anafranil</em></p><p>Concomitant administration of CYP2D6 inhibitors may lead to an increase in concentration of both active components, up to ~3-fold in patients with a debrisoquine/sparteine extensive metabolizer phenotype, converting them to a poor-metabolizer phenotype. Concomitant administration of CYP1A2, CYP2C19 and CYP3A4 inhibitors are expected to increase clomipramine concentrations and decrease <em>N</em>-desmethylclomipramine, thus not necessarily affecting the overall pharmacology.</p><p><strong>&nbsp;</strong></p><p>Terbinafine</p><p>Coadministration of Anafranil with oral antifungal terbinafine, a strong inhibitor of CYP2D6, may result in increased exposure and accumulation of clomipramine and its N-demethylated metabolite. Therefore, dose adjustments of Anafranil may be necessary when coadministered with terbinafine.</p><p>&nbsp;</p><p>Cimetidine</p><p>Coadministration with the histamine<sub>2</sub> (H<sub>2</sub>)-receptor antagonist, cimetidine (an inhibitor of several P450 enzymes, including CYP2D6 and CYP3A4), may increase plasma concentrations of tricyclic antidepressants, whose dosage should therefore be reduced.</p><p>&nbsp;</p><p>Oral contraceptives</p><p>No interaction between chronic oral contraceptive use (15 or 30 micrograms ethinyl estradiol daily) and Anafranil (25 mg daily) has been documented. Estrogens are not known to be inhibitors of CYP2D6, the major enzyme involved in clomipramine clearance and, therefore, no interaction is expected. Although, in a few cases with high dose estrogen (50 micrograms daily) and the tricyclic antidepressant imipramine, increased side effects and therapeutic response were noted, it is unclear as to the relevance of these cases to clomipramine and lower dose estrogen regimens. Monitoring therapeutic response of tricyclic antidepressants at high dose estrogen regimens (50 micrograms daily) is recommended and dose adjustments may be necessary.</p><p><strong>&nbsp;</strong></p><p>Antipsychotics</p><p>Comedication of antipsychotics (e.g. phenothiazines) may result in increased plasma levels of tricyclic antidepressants, a lowered convulsion threshold, and seizures. Combination with thioridazine may produce severe cardiac arrhythmias.</p><p>&nbsp;</p><p>Methylphenidate</p><p>Methylphenidate may also increase concentrations of tricyclic antidepressants by potentially inhibiting their metabolism and a dose reduction of the tricyclic antidepressant may be necessary.</p><p>&nbsp;</p><p>Valproate</p><p>Concomitant administration of valproate with clomipramine may cause inhibition of CYP2C and/or UGT enzymes resulting in increased serum levels of clomipramine and desmethylclomipramine.</p><p>&nbsp;</p><p>Grapefruit, grapefruit juice, or cranberry juice</p><p>Concomitant administration of Anafranil with grapefruit, grapefruit juice, or cranberry juice may increase the plasma concentrations of clomipramine.</p><p>&nbsp;</p><p><em>Interactions resulting in decreased effect of Anafranil</em></p><p>Rifampicin</p><p>Rifampicin (CYP3A and CYP2C inducer), may decrease clomipramine concentrations as concomitant administration of drugs known to induce cytochrome P450 enzymes, particularly CYP3A4, CYP2C19 may accelerate the metabolism and decrease the efficacy of Anafranil.</p><p><strong>&nbsp;</strong></p><p>Anticonvulsants</p><p>Anticonvulsants (CYP3A and CYP2C inducer) e.g. barbiturates, carbamazepine, phenobarbital and phenytoin, may decrease clomipramine concentrations as concomitant administration of drugs known to induce cytochrome P450 enzymes, particularly CYP3A4, CYP2C19 may accelerate the metabolism and decrease the efficacy of Anafranil.</p><p>&nbsp;</p><p>Cigarette smoking</p><p>Known inducers of CYP1A2 (e.g. nicotine/components in cigarette smoke), decrease plasma concentrations of tricyclic drugs. In cigarette smokers, clomipramine steady-state plasma concentrations were decreased 2-fold compared to non-smokers (no change in <em>N</em>-desmethylclomipramine).</p><p>&nbsp;</p><p>Colestipol and cholestyramine</p><p>Concomitant administration of ion exchange resins such as cholestyramine or colestipol may reduce the plasma levels of clomipramine. Staggering the dosage of clomipramine and resins, such that the drug is administered at least 2 h before or 4-6 h after the administration of resins, is recommended.</p><p>&nbsp;</p><p>St. John&rsquo;s wort</p><p>Concomitant administration of Anafranil with St. John&rsquo;s wort during the treatment may decrease the plasma concentrations of clomipramine.</p><p>&nbsp;</p><p><u>Interactions affecting other drugs</u></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Anticholinergic agents</em></strong></p><p>Tricyclic antidepressants may potentiate the effects of these drugs (e.g. phenothiazine, antiparkinsonian agents, antihistamines, atropine, biperiden) on the eye, central nervous system, bowel and bladder.</p><p>&nbsp;</p><p><strong><em>Antiadrenergic agents</em></strong></p><p>Anafranil may diminish or abolish the antihypertensive effects of adrenergic neuron blockers such as guanethidine, betanidine, reserpine, clonidine and alpha-methyldopa. Patients requiring comedication for hypertension should therefore be given antihypertensives of a different type (e.g. vasodilators, or beta-blockers).</p><p>&nbsp;</p><p><strong><em>CNS depressants</em></strong></p><p>Tricyclic antidepressants may potentiate the effects of alcohol and other central depressant substances (e.g. barbiturates, benzodiazepines, or general anaesthetics).</p><p><strong>&nbsp;</strong></p><p><strong><em>Sympathomimetic drugs</em></strong></p><p>Anafranil may potentiate the cardiovascular effects of sympathomimetics such as adrenaline, noradrenaline, isoprenaline, ephedrine and phenylephrine (e.g. local anaesthetics).</p><p><em>&nbsp;</em></p><p><strong><em>Anticoagulants</em></strong></p><p>Some tricyclic antidepressants may potentiate the anticoagulant effect of coumarin drugs, such as warfarin, and this may be through inhibition of their metabolism (CYP2C9). There is no evidence for the ability of clomipramine to inhibit the metabolism of anticoagulants, such as warfarin, however, careful monitoring of plasma prothrombin has been advised for this class of drug.</p><p>&nbsp;</p><p>Clomipramine is also an in vitro (<em>K</em><sub>i</sub> = 2.2 microM) and in vivo inhibitor of CYP2D6 activity (sparteine oxidation) and therefore, may cause increased concentrations of co-administered compounds that are primarily cleared by CYP2D6 in extensive metabolizers</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Women of child-bearing potential</strong></p><p>There are no data supporting any special recommendations in women of child-bearing potential.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy</strong></p><p>There is limited amount of data from the use of Anafranil in pregnant women that indicates a potential to harm the foetus or cause congenital malformation. Anafranil should be used during pregnancy only if the potential benefit outweighs the potential risk to the foetus.</p><p>Neonates whose mothers had taken tricyclic antidepressants until delivery showed drug withdrawal symptoms, such as dyspnoea, lethargy, colic, irritability, hypotension or hypertension, and tremor/spasms/convulsions, during the first few hours or days. To avoid such symptoms, ANAFRANIL<strong> </strong>should if possible be gradually withdrawn at least 7 weeks before the calculated date of confinement.</p><p>&nbsp;</p><p><strong>Lactation</strong></p><p>Since the active substance passes into the breast milk, ANAFRANIL should be gradually withdrawn or the infant weaned if the patient is breast-feeding.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Fertility</strong></p><p>No adverse effects on reproductive performance, including male and female fertility, were observed in rats at oral doses up to 24 mg/kg. (see section 5.3. Preclinical safety data)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients receiving ANAFRANIL should be warned that blurred vision and other nervous system and psychiatric related disorders such as somnolence, disturbance in attention, confusion, disorientation, aggravation of depression, delirium etc. (see section 4.8) may occur, in which case they should not drive, operate machinery, or do anything else requiring alertness.</p><p>Patients should also be warned that alcohol or other drugs may potentiate these effects (see section 4.5&nbsp;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>Unwanted effects are usually mild and transient, disappearing under continued treatment or with a reduction in the dosage. They do not always correlate with plasma drug levels or dose. It is often difficult to distinguish certain undesirable effects from symptoms of depression such as fatigue, sleep disturbances, agitation, anxiety, constipation, and dry mouth.</p><p>If severe neurological or psychiatric reactions occur, ANAFRANIL should be withdrawn.</p><p>Adverse reactions are ranked under heading of frequency, the most frequent first, using the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100, &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1&nbsp;000, &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10&nbsp;000, &lt;&nbsp;1/1&nbsp;000) very rare (&lt;&nbsp;1/10&nbsp;000), including isolated reports.</p><p>Table1 Summary of adverse drug reactions</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Leukopenia, agranulocytosis, thrombocytopenia, eosinophilia,</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sinus tachycardia, palpitation, orthostatic hypotension, clinically irrelevant ECG changes (e.g. ST and T changes) in patients of normal cardiac status</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Arrhythmias, blood pressure increased</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Conduction disorder (e.g. widening of QRS complex, prolonged QT interval, PQ changes, bundle-branch block, torsade de pointes, particularly in patients with hypokalaemia)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Tinnitus &nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Inappropriate antidiuretic hormone secretion (SIADH) &nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Accommodation disorder, vision blurred</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Mydriasis &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Glaucoma &nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea dry mouth, constipation</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting, gastrointestinal disorder, diarrhoea</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Fatigue &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Oedema (local or generalised), alopecia hyperpyrexia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hepatitis with or without jaundice</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Anaphylactic and anaphylactoid reactions including hypotension</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Weight increase</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Transaminases increased</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Electroencephalogram abnormal</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Increased appetite</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Muscular weakness &nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Dizziness, tremor, headache, myoclonus, somnolence &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;Speech disorder, paraesthesia, hypertonia, dysgeusia, memory impairment, disturbance in attention</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Convulsions, ataxia</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Neuroleptic malignant syndrome</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Restlessness &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Confusional state, disorientation, hallucinations (particularly in elderly patients and patients with Parkinson&#39;s disease), anxiety, agitation, sleep disorder, mania, hypomania, aggression, depersonalisation, aggravation of depression, insomnia, nightmares, delirium</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Activation of psychotic symptoms</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Micturition disorder</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Urinary retention &nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Libido disorder, erectile dysfunction</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Galactorrhoea, breast enlargement &nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic, and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Yawning</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Alveolitis allergic (pneumonitis) with or without eosinophilia</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Hyperhidrosis &nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dermatitis allergic (skin rash, urticaria), photosensitivity reaction, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Purpura</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hot flush</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Additional adverse drug reactions from post-marketing spontaneous reports</strong></p><p>The following additional adverse drug reactions have been identified with Anafranil oral or im/iv dosage forms based on post-marketing spontaneous reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency</p><p>&nbsp;</p><p><strong>Nervous system disorders</strong></p><p>Frequency not unknown: Serotonin syndrome, extrapyramidal disordersymptoms (including akathisia and tardive dyskinesia).</p><p>&nbsp;</p><p><strong>Musculoskeletal and connective tissue disorders</strong></p><p>Frequency not unknown: Rhabdomyolysis (as a complication of neuroleptic malignant syndrome) .</p><p>&nbsp;</p><p><strong>Reproductive system and breast disorders</strong></p><p>Frequency not known: Ejaculation failure, Ejaculation delayed</p><p>&nbsp;</p><p><strong>Investigations</strong></p><p>Frequency not unknown: Blood prolactin increased &nbsp;</p><p>&nbsp;</p><p><strong>Withdrawal symptoms</strong></p><p>The following symptoms commonly occur after abrupt withdrawal or reduction of the dose: nausea, vomiting, abdominal pain, diarrhoea, insomnia, headache, nervousness, and anxiety (see section 4.4)</p><p>&nbsp;</p><p><strong>Bone fractures</strong></p><p>Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and tricyclic antidepressants. The mechanism leading to this risk is unknown.</p><p>&nbsp;</p><p><strong>Geriatric population</strong></p><p>Elderly patients are particularly sensitive to anticholinergic, neurological, psychiatric, or cardiovascular effects. Their ability to metabolisze and eliminate drugs may be reduced, leading to a risk of elevated plasma concentrations at therapeutic doses</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to:: Bulgarian Drug Agency, 8 Damyan Gruev str., 1303 Sofia; tel: +359 2 8903417; website: www.bda.bg.</p><p>&nbsp;</p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>O Toll Free Number: 8001240078</p><p>O Phone: +966112658100<br />O Fax: +966112658107<br /><strong><em>O Email: </em></strong><strong><em>adverse.events@novartis.com</em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p>-- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The signs and symptoms of overdose with Anafranil are similar to those reported with other tricyclic antidepressants. Cardiac abnormalities and neurological disturbances are the main complications.</p><p>&nbsp;</p><p>In children, accidental ingestion of any amount should be regarded as serious and potentially fatal.</p><p>&nbsp;</p><p><strong>Signs and symptoms</strong></p><p>Symptoms generally appear within 4 hours of ingestion and reach maximum severity after 24&nbsp;hours. Owing to delayed absorption (anticholinergic effect), long half-life, and enterohepatic recycling of the drug, the patient may be at risk for up to 4-6 days.</p><p>The following signs and symptoms may be seen:</p><p>&nbsp;</p><p><strong><em>Central nervous system</em></strong></p><p>Drowsiness, stupor, coma, ataxia, restlessness, agitation, enhanced reflexes, muscular rigidity and choreoathetosis, convulsions. In addition, symptoms consistent with Serotonin Syndrome (e.g. hyperpyrexia, myoclonus, delirium and coma) may be observed.</p><p>&nbsp;</p><p><strong><em>Cardiovascular system</em></strong></p><p>Hypotension, tachycardia, arrhythmias, QTc prolongation and arrhythmias including torsades de pointes, condition disorders, shock, heart failure, in very rare cases cardiac arrest.</p><p>Respiratory depression, cyanosis, vomiting, fever, mydriasis, sweating, and oliguria or anuria may also occur.</p><p>&nbsp;</p><p><strong>Treatment</strong></p><p>There is no specific antidote, and treatment is essentially symptomatic and supportive.</p><p>Anyone suspected of receiving an overdose of Anafranil, particularly children, should be hospitalised and kept under close surveillance for at least 72 hours.</p><p>Perform gastric lavage or induce vomiting as soon as possible if the patient is alert. If the patient is not alert, secure the airway with a cuffed endotracheal tube before beginning lavage, and do not induce vomiting. These measures are recommended for up to 12 hours or even longer after the overdose, since the anticholinergic effect of the drug may delay gastric emptying. Administration of activated charcoal may help to reduce drug absorption.</p><p>Since it has been reported that physostigmine may cause severe bradycardia, asystole, and seizures, its use is not recommended in cases of overdosage with Anafranil. Haemodialyses or peritoneal dialyses are ineffective because of the low plasma concentrations of clomipramine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group</strong></p><p>Pharmacotherapeutic group: Tricyclic antidepressant. Noradrenaline and preferential serotonin-reuptake inhibitor (non selective monoamine reuptake inhibitors), ATC code: N06A&nbsp;A04.</p><p><strong>&nbsp;</strong></p><p><strong>Mechanism of action</strong></p><p>The therapeutic activity of Anafranil is believed to be based on its ability to inhibit the neuronal re-uptake of noradrenaline and serotonin released in the synaptic cleft, with inhibition of 5-HT reuptake being the more important of these activities.</p><p>Anafranil also has a wide pharmacological spectrum of action, which includes alpha1-adrenolytic, anticholinergic, antihistaminic, and antiserotonergic (5-HT-receptor blocking) properties.</p><p>&nbsp;</p><p><strong>Pharmacodynamic effects</strong></p><p>ANAFRANIL acts on the depressive syndrome as a whole, including in particular typical features such as psychomotor retardation, depressed mood, and anxiety. The clinical response usually sets in after 2-3 weeks of treatment.</p><p>ANAFRANIL also exerts a specific effect on obsessive-compulsive disorder distinct from its antidepressant effects. In chronic pain with or without somatic causes, ANAFRANIL acts presumably by facilitating serotonin and noradrenaline neurotransmission.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Clomipramine is completely absorbed from the gastrointestinal tract. The systemic bioavailability of unchanged clomipramine is reduced to about 50% by hepatic first-pass metabolism to the active metabolite, <em>N</em>-desmethylclomipramine. &nbsp;Following administration of 25 mg coated tablet, the mean maximum plasma concentration (Cmax) of clomipramine were 63.37 &plusmn; 12.71 ng/mL (Tmax 4.83 &plusmn; 0.39 hr). The dose of 75 mg daily, administered either as coated tablets of 25 mg t.i.d., produces steady-state plasma concentrations ranging from about 20 to 175 ng/mL</p><p>&nbsp;</p><p>The steady-state plasma concentrations of the active metabolite <em>N</em>-desmethylclomipramine follow a similar pattern. However, at a dose of 75&nbsp;mg Anafranil per day, they are 40-85% higher than those of clomipramine.</p><p><strong>&nbsp;</strong></p><p><strong>Distribution</strong></p><p>Clomipramine is 97.6% bound to plasma proteins. The apparent distribution volume is about 12 to 17&nbsp;l/kg bodyweight. Concentrations in cerebrospinal fluid are about 2% of the plasma concentration. Clomipramine passes into maternal milk in concentrations similar to those in plasma.</p><p><strong>&nbsp;</strong></p><p><strong>Biotransformation</strong></p><p>The primary route of clomipramine metabolism is demethylation to form the active metabolite, <em>N</em>-desmethylclomipramine. <em>N</em>-desmethylclomipramine can be formed by several P450 enzymes, primary CYP3A4, CYP2C19, and CYP1A2. Clomipramine and <em>N</em>-desmethylclomipramine are hydroxylated to form 8‑hydroxyclomipramine or 8-hydroxy-<em>N</em>-desmethylclomipramine. The activity of the 8‑hydroxy metabolites are not defined in vivo. Clomipramine is also hydroxylated at the 2-position and <em>N</em>-desmethylclomipramine can be further demethylated to form didesmethylclomipramine. The 2- and 8- hydroxy metabolites are excreted primarily as glucuronides in the urine. Elimination of the active components, clomipramine and <em>N</em>-desmethylclomipramine, by formation of 2- and 8-hydroxy clomipramine is catalysed by CYP2D6.</p><p><strong>&nbsp;</strong></p><p><strong>Elimination</strong></p><p>Clomipramine is eliminated from the blood with a mean half-life of 21&nbsp;h (range: 12-36&nbsp;h), and desmethylclomipramine with a mean half-life of 36&nbsp;h.</p><p>About two thirds of a single dose of clomipramine are excreted in the form of water-soluble conjugates in the urine and approximately one third in the faeces. The quantity of unchanged clomipramine and desmethylclomipramine excreted in the urine is about 2% and 0.5% of the dose administered, respectively.</p><p><strong>&nbsp;</strong></p><p><strong>Food effect</strong></p><p>Food has no significant impact on the pharmacokinetics of clomipramine. A slight delay in the onset of absorption may be observed with the administration of Anafranil with food <strong>Dose proportionality</strong></p><p>The drug follows dose-proportionate pharmacokinetics over a dose range of 25 to 150 mg &nbsp;</p><p>&nbsp;</p><p><strong>Effect of age</strong></p><p>In elderly patients, clomipramine has relatively low clearance in comparison to younger adult patients. It is reported to reach a therapeutic steady state at doses lower than that reported for middle-age patients. Clomipramine should be used with caution in elderly patients.</p><p>&nbsp;</p><p><strong>Renal impairment</strong></p><p>There are no specific reports describing the pharmacokinetic of the drug in patients with renal impairment. Although the drug is excreted as inactive metabolites in the urine and feces, the accumulation of inactive metabolites may subsequently result in the accumulation of the parent drug and its active metabolite. In moderate and severe renal impairment, it is recommended to monitor the patient during the treatment.</p><p>&nbsp;</p><p><strong>Hepatic impairment</strong></p><p>Clomipramine is extensively metabolized in the liver by CYP2D6, CYP3A4, CYP2C19 and CYP1A2, hepatic impairment may impact on its pharmacokinetics. In patients with liver impairment, clomipramine should be administered with caution.</p><p>&nbsp;</p><p><strong>Ethnic sensitivity</strong></p><p>Although the impact of ethnic sensitivity and race on the pharmacokinetics of clomipramine has not been studied extensively, the metabolism of clomipramine and its active metabolite is governed by genetic factors leading to poor and extensive metabolism of the drug and its metabolite. The metabolism of clomipramine in Caucasians population may not be extrapolated to Asians, in particular, Japanese and Chinese because of the pronounced differences of metabolism of clomipramine between these two ethnic groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Repeat-dose toxicity</strong></p><p>Phospholipidosis and testicular changes, commonly associated with tricyclic compounds, have been observed with clomipramine hydrochloride at doses &gt;10 fold greater than the maximum recommended human daily dose.</p><p>&nbsp;</p><p><strong>Reproductive toxicity</strong></p><p>No adverse effects on reproductive performance, including male and female fertility, were observed in rats at oral doses up to 24 mg/kg.</p><p>No teratogenic effects were detected in mice, rats, and rabbits at doses up to 100, 50, and 60 mg/kg, respectively (See section 5.3. Preclinical safety data)</p><p><strong>&nbsp;</strong></p><p><strong>Mutagenicity</strong></p><p>Various in vitro and in vivo mutagenicity tests were performed and did not reveal any mutagenic activity of clomipramine hydrochloride.</p><p>&nbsp;</p><p><strong>Carcinogenicity</strong></p><p>There was no evidence of carcinogenicity in mice and rats after 104 weeks of treatment with clomipramine hydrochloride.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, Magnesium stearate, Maize starch, Silica colloidal anhydrous, Hypromellose (hydroxypropyl methylcellulose), Copovidone (vinylpyrrolidone-vinylacetate copolymer), Cellulose microcrystalline, Titanium dioxide (Е171), Iron oxide, yellow (Е172), Macrogol 8 000 (polyethylene glycol 8 000), Povidone (polyvinylpyrrolidone), Sucrose, Talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&ordm;C</p><p>Store the product in the original package, in order to protect from moisture.</p><p>To be kept out of the reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PE/PVDC blisters</p><p>10 mg x 30 coated tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no special precautions for use and handling.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                approved by Novartis Pharmaceutical Company in 01/2015 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>